POTS symptoms are not “all in your head.” It is a real condition that affects teens and adults and can be diagnosed via specific tests.
Patients with postural orthostatic tachycardia syndrome (POTS) face extraordinary challenges. Not only is this condition often misdiagnosed, but follow-up care and treatment can also be hard to find. The POTS program at Johns Hopkins — which has one of the few POTS centers in the U.S. — is dedicated to treating adults and children with POTS.
POTS is real
POTS is treatable
POTS symptoms respond to certain treatments, and many patients are able to reduce the frequency of flare-ups and live a more functional life.
POTS is a chronic illness
While some people with POTS do recover and many see some improvement over time, most need long-term follow up care.
How Our POTS Program Can Help
-
Our Team
Learn about the Johns Hopkins team of POTS experts.
-
Our Treatment Approach
Find out how we can help you manage your POTS.
Request An Appointment
Our Locations
You can find Johns Hopkins POTS specialists in each of these locations.
Lutherville
Johns Hopkins Health Care & Surgery Center - Green Spring Station
10803 Falls Rd.
Lutherville, MD 21093
Baltimore
Johns Hopkins Bayview Medical Center
4940 Eastern Ave.
Baltimore, MD 21224
Timonium
Coppermine Health & Fitness Center
110 W Timonium Rd.
Lutherville-Timonium, MD 21093
110 W Timonium Rd.
Lutherville-Timonium, MD 21093
Ongoing Trial
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS (POTS)
A phase 2 randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of efgartigimod IV in adult patients with post–COVID-19 postural orthostatic tachycardia syndrome (POTS).
Study ID: IRB00333396
Principle Investigator: Tae Chung, M.D.
Contact: Call 410-550-4896 or email Taylor Bopp at [email protected] with any questions on the trial.
-
Efgartigimod is a neonatal Fc receptor (FcRn) antagonist in clinical development for treating autoimmune diseases mediated by immunoglobulin G (IgG) autoantibodies. POTS arising in patients after infection with the SARS-CoV-2 virus (COVID-19) may be caused by pathogenic IgG autoantibodies that lead to autonomic dysfunction. This phase 2 study will evaluate the efficacy and safety of weekly infusion of efgartigimod in participants with post–COVID-19 POTS over 6 months.
-
- Age 19 or older
- Evidence of prior COVID-19 infection by documented PCR test
- New onset of the following symptoms that were not present prior to COVID-19 infection: chronic fatigue, difficulty standing up, brain fog, exercise intolerance, palpitation, nausea, chronic constipation/diarrhea, anxiety, chest pain, headache and blood pooling.
- No prior history of pre-existing POTS or autonomic neuropathy
Featured Articles
COVID-19 and POTS: Is There a Link?
Although many people recover quickly from COVID-19, the disease caused by the coronavirus, others who recover may continue to experience symptoms for months. Researchers are still determining the cause of these extended symptoms, but some COVID-19 "long-haulers" may actually be dealing with POTS.
POTS: A Little-Known Cause of Extreme Fatigue
While there are many causes of fatigue, one of them is frequently missed and misdiagnosed: postural orthostatic tachycardia syndrome (POTS). Physical medicine and neuromuscular specialist Tae Chung, M.D., answers questions about POTS and extreme fatigue as one of its symptoms.